Financial Data and Key Metrics Changes - Baxter reported fourth quarter 2024 global sales from continuing operations of $2.75 billion, an increase of 1% on a reported basis and 2% on a constant-currency basis, exceeding previous guidance which anticipated a low single-digit decline [26][27] - Adjusted earnings per share from continuing operations for the fourth quarter were $0.58, surpassing prior guidance of $0.50 to $0.53 per share, despite an 11% year-over-year decline primarily due to Hurricane Helene's impact [28][52] - For the full year 2024, Baxter reported sales from continuing operations of $10.6 billion, a 3% increase on both a reported and constant-currency basis, with adjusted earnings per share totaling $1.89, reflecting an 11% increase over the prior year [27][53] Business Line Data and Key Metrics Changes - In the Medical Products & Therapies (MPT) segment, fourth quarter sales were $1.3 billion, a 1% increase, with full year sales totaling $5.2 billion, advancing 5% [30][31] - The Infusion Therapies & Technologies division within MPT reported fourth quarter sales of $1 billion, a 1% decrease, while Nutrition sales advanced double-digits globally [32] - The Pharmaceuticals segment saw fourth quarter sales of $643 million, an 8% increase, with full year sales reaching $2.4 billion, a 7% increase [39][40] Market Data and Key Metrics Changes - U.S. capital orders for Care & Connectivity Solutions rose 9% in the fourth quarter and increased 15% for the full year, indicating strong demand in the market [36] - Frontline care sales in the fourth quarter were $280 million, an 8% decline, attributed to backlog reductions and supply constraints [37] - The overall capital environment for patient monitoring devices and hospital equipment remains strong, with a 15% growth in capital orders year-over-year [102] Company Strategy and Development Direction - Baxter is focused on customer-inspired innovation, optimizing its structure post-Kidney Care divestiture, and driving commercial excellence [81][83] - The company aims to achieve a target leverage ratio of around 3x net debt-to-EBITDA by the end of 2025, following significant debt repayment initiatives [90][92] - The strategic actions taken, including the implementation of a verticalized operating model, are expected to enhance agility and focus on profitable growth [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from Hurricane Helene and anticipates stabilization in the primary care market, which is expected to positively impact performance in 2025 [71][73] - The outlook for 2025 includes total sales growth of 5% to 6% on a reported basis, with operational sales growth expected to be 4% to 5% [54][60] - Management highlighted the importance of new product launches, particularly in the Infusion Therapies segment, which is expected to drive significant growth [98][122] Other Important Information - The company completed the sale of Vantive on January 31, 2025, marking a significant milestone in its transformation efforts [12][13] - Adjusted gross margin from continuing operations for the fourth quarter was 44.5%, reflecting a sequential improvement [45] - The company plans to offset stranded costs from the Kidney Care divestiture through income from transition services agreements and cost containment initiatives [44] Q&A Session Summary Question: How should we think about the cadence for 2025? - Management indicated a conservative approach for the first quarter due to ongoing recovery from Hurricane Helene, with expectations for a stronger performance in the fourth quarter [67][68] Question: What is the latest on the HST business, especially frontline care? - Management anticipates stabilization in the primary care market and expects to overcome previous headwinds, with a stronger order book heading into 2025 [72][75] Question: Can you discuss the direction of the company post-Vantive? - Management emphasized a focus on customer-inspired innovation, targeted market investments, and optimizing the company's structure for growth [80][82] Question: What is the post-Vantive capital structure and target leverage ratios? - The target leverage ratio is around 3x net debt-to-EBITDA, with expectations to achieve this by the end of 2025 following significant debt repayments [89][90] Question: Can you elaborate on new product investments and their timing? - Management highlighted ongoing innovation across the portfolio, particularly in the Infusion Therapies and Pharmaceuticals segments, with expectations for continued growth in 2025 [97][98]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) (Commission File Number) 1-4448 36-0781620 (I.R.S. Employer Identification No.) One Baxter Parkway, Deerfield, Illinois 60015 (Address of pri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

Baxter International Inc. (NYSE:BAX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman, President and Chief Executive Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Lawrence Biege ...

______________________ Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2024 RESULTS • Baxter third-quarter 2024 sales totaled $3.85 billion • Third-quarter total Baxter U.S. GAAP diluted earnings per share (EPS) were $0.27 ; adjusted total Baxter diluted EPS were $0.80 , exceeding the company's previously issued guidance • Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis , reflecting growth across all segments • Third ...

Baxter International Inc. (NYSE:BAX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Securities David Roman - Goldman Sachs Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Danielle Antalffy - UBS Mat ...

SECOND-QUARTER 2024 EARNINGS Baxter International Inc. August 6, 2024 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements concerning the company's financial results (including the outlook for third-quarter and full-year 2024) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 BAXTER INTERNATIONAL INC. FORM 10-Q For the quarterly period ended June 30, 2024 TABLE OF CONTENTS | | | Page Number | | --- | --- ...

BAXTER REPORTS SECOND-QUARTER 2024 RESULTS DEERFIELD, Ill., AUG. 6, 2024 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2024. "Baxter's strategic transformation continues to gain momentum and drive performance benefiting our broad range of stakeholders," said José (Joe) E. Almeida, chair, president and chief executive officer. "In addition to delivering positive top-line and bottom-line results in Q2 2024, Baxter's portfolio of medically ess ...

FI RS T-Q UA RT ER 2024 EA RNI NGS Baxter International Inc. May 2, 2024 1 FORWA R D- LOOKING STAT EM ENT S ...